Increased emphasis in recent years on DNA/mRNA macromolecule-based therapeutic drugs.

Formulation excipients and their role in increasing the drug product stability are discussed.

Chemical liabilities, major degradation routes and characterization methods are reviewed.

Advanced formulations for some of the targeted delivery challenges are discussed.

Glossary of current clinical stage assets of nucleic-acid-based therapeutics is included.